Catalyst
Slingshot members are tracking this event:
Genfit NASH program targeting Nonalcoholic Steatohepatitis with Elafibranor (GFT505) plans to complete Phase 3 enrollment in the first quarter of 2018
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 11, 2018
Occurred Source:
http://www.genfit.com/wp-content/uploads/2018/04/2018.04.11-PR-GENFIT-RESOLVE-IT.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Study, Complete Enrollment, Elafibranor (gft505, Nonalcoholic Steatohepatitis, Nash
